Patents by Inventor Patrice Jichlinski

Patrice Jichlinski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • strains for use in the treatment and/or prevention of cancer
    Patent number: 9795641
    Abstract: The present invention relates to a pharmaceutical composition comprising a live attenuated non-recombinant mutant of Salmonella enterica serovar typhi strain and/or a non-viable attenuated non-recombinant mutant of Salmonella enterica serovar typhi strain for use the treatment of cancer recurrence/progression. Preferably the cancer is bladder cancer.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: October 24, 2017
    Assignee: CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (C.H.U.V.)
    Inventors: Denise Nardelli Haefliger, Patrice Jichlinski, Sonia Domingos Pereira
  • SALMONELLA STRAINS FOR USE IN THE TREATMENT AND/OR PREVENTION OF CANCER
    Publication number: 20160074441
    Abstract: The present invention relates to a pharmaceutical composition comprising a live attenuated non-recombinant mutant of Salmonella enterica serovar typhi strain and/or a non-viable attenuated non-recombinant mutant of Salmonella enterica serovar typhi strain for use the treatment of cancer recurrence/progression. Preferably the cancer is bladder cancer.
    Type: Application
    Filed: May 7, 2014
    Publication date: March 17, 2016
    Inventors: Denise NARDELLI HAEFLIGER, Patrice JICHLINSKI, Sonia DOMINGOS PEREIRA
  • Solution for diagnosing or treating tissue pathologies
    Patent number: 7348361
    Abstract: The invention concerns a 5-aminolevulinic acid ester (E-ALA) solution for producing a pharmaceutical preparation useful for diagnosing and/or treating tissue and/or cell pathologies by local radiation exposure using radiation emitted by a light source energy followed, in the case diagnosis, by detection of fluorescent protoporphyrin IX (Pp1X). The E-ALA concentration in the solution is less than 1% and ranges between 0.01% and 0.5%. The low E-ALA concentration in the solution increases Pp1X synthesis and homogenises its distribution in the cell layers while highly reducing the secondary toxicity for the treated cells.
    Type: Grant
    Filed: April 22, 1999
    Date of Patent: March 25, 2008
    Assignee: Ecole Polytechnique Federale de Lausanne
    Inventors: Alexandre Marti, Norbert Lange, Matthieu Zellweger, Georges Wagnieres, Hubert Van Den Bergh, Patrice Jichlinski, Pavel Kucera
  • Solution for diagnosing or treating tissue pathologies
    Publication number: 20030158258
    Abstract: The invention concerns a 5-aminolevulinic acid ester (E-ALA) solution for producing a pharmaceutical preparation useful for diagnosing and/or treating tissue and/or cell pathologies by local radiation exposure using radiation emitted by a light source energy followed, in the case diagnosis, by detection of fluorescent protoporphyrin IX (Pp1X). The E-ALA concentration in the solution is less than 1% and ranges between 0.01% and 0.5%. The low E-ALA concentration in the solution increases Pp1X synthesis and homogenises its distribution in the cell layers while highly reducing the secondary toxicity for the treated cells.
    Type: Application
    Filed: October 20, 2000
    Publication date: August 21, 2003
    Inventors: Alexandre Marti, Norbert Lange, Mattieu Zellweger, Georges Wagnieres, Hubert Van Dew Bergh, Patrice Jichlinski, Pavel Kucera